Press "Enter" to skip to content

Johnson & Johnson Vaccine Could be Less Efficient against Delta Variant, Reveals New Study

According to a new study posted online Tuesday, the one-shot coronavirus Vaccine from Johnson & Johnson Vaccine is much less effective against the Delta variant than it is against the original version of COVID-19. The study examined blood samples in a laboratory setting and has not yet been peer-reviewed, suggesting that anyone who received the Johnson & Johnson may need to receive a second shot as the variant continues to spread across the US.

Nathaniel Landau, a virologist at NYU’s Grossman School of Medicine and study leader, said that the message that we wanted to give was not that people shouldn’t get the J&J Vaccine But they also hope that in the future, it will be boosted with either another dose of J&J or a boost with Pfizer or Moderna.

Earlier this month, New Jersey-based Johnson & Johnson published preliminary data indicating its was effective against the Delta variant, first located in India, at least eight months after inoculation.In May, the British government released a study indicating that a single dose of the AstraZeneca, which is similar in structure to the Johnson & Johnson Vaccine, was just 33% effective against symptomatic disease caused by the Delta variant, while two doses were 60% effective against the symptomatic disease.

 J&J spokesperson told the data from the latest study do not speak of immune protection. Last month, Centers for Disease Control and Prevention Director Dr. Rochelle Walensky said that we have every reason to believe that the J&J will perform well against the Delta variant, as it has so far against other variants circulating in the United States.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *